Conventional type 1 dendritic cells (cDC1) in cancer immunity

Cancer immunotherapy, alone or in combination with conventional therapies, has revolutionized the landscape of antineoplastic treatments, with dendritic cells (DC) emerging as key orchestrators of anti-tumor immune responses. Among the distinct DC subsets, conventional type 1 dendritic cells (cDC1) have gained prominence due to their unique ability to cross-present antigens and activate cytotoxic T lymphocytes. This review summarizes the distinctive characteristics of cDC1, their pivotal role in anticancer immunity, and the potential applications of cDC1-based strategies in immunotherapy.

Automated summary

This review summarizes the importance of dendritic cells, particularly conventional type 1 dendritic cells (cDC1), in anti-tumor immunity and their potential applications in immunotherapy.